Clinical Trial Update: CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This update describes a Phase 1/2 clinical trial of CD19 CAR-T cells with CRS suppression technology for relapsed/refractory CD19-positive acute lymphoblastic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19 CAR-T Cells with CRS Suppression Technology

Snippet

Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Conditions: Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1, Phase 2 | Status: UNKNOWN